Compugen Ltd is a biotechnology company that focuses on the discovery and development of novel drug candidates for immuno-oncology and autoimmune diseases
Utilizing its proprietary algorithmic technology platform, the company identifies new therapeutic targets and generates potential antibody candidates. Compugen is engaged in both internal drug development and collaboration with pharmaceutical partners, aiming to enhance treatment options for patients through innovative therapies that leverage the body's immune system to fight cancer and other conditions.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday. The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The S&P 500 also rose, gaining, 0.45% to 4,762.12.
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&P 500 also rose, gaining, 0.38% to 4,758.55.
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
U.S. stocks traded higher this morning, with the Dow Jones index gaining around more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.17% to 37,369.84 while the NASDAQ rose 0.25% to 14,941.77. The S&P 500 also rose, gaining, 0.17% to 4,748.81.
Compugen Ltd. (NASDAQ: CGEN) is one today’s most active stocks by volume. So far today, approximately 61,549 shares of Compugen Ltd. have been exchanged, as compared to an average 30-day volume of 128.42k shares.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.
A support line is a price level where a stock historically stops declining. It can be a flat line all at one price, or it can be a trend line that gradually moves in one direction. Here is a closer look at how this may benefit you.
In the past week, there has been a strong surge in interest in biotech stocks and that is a trend that investors ought to look into. Considering the fact that it is a highly innovative sector, it may well be a good move to keep an eye on. There have been certain biotech stocks that have managed to record massive gains in the past week and here is a look at four of those.
